iBio, Inc.

NASDAQ:IBIO

Biotechnology

Healthcare
$0.85 +0.00%

+$0.00 today

Market cap
$59.75M
Beta
1.29
P/E (TTM)
-3.6
EPS (TTM)
-$0.32
52W Low $0.78High $3.82

Volume 0.84M

Average 0.81M

IBIO Total Debt

Short-term and long-term borrowings combined.

iBio, Inc.NASDAQ: IBIO

Total Debt · Q4 FY2026 · quarter ended Jun 2026

Total debt falls 37.3% from a year ago

Total debt stood at $2.2M at the end of Q4 FY2026, down 37.3% from a year earlier and down 5.5% from the prior quarter. Over 3 fiscal years it compounded at -49.5% a year.

Context

  • Total debt amounted to 2.2% of total assets at the end of Q4 FY2026, down 12.9 pp from a year earlier.
  • Total debt increased in 0 of the last 3 fiscal years.
  • FY2026 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -37.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.2M-5.5% QoQ
Last fiscal yearJun 2026
$2.2M-37.3% YoY
Year agoJun 2025
$3.51M-37.3% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-37.3%——
1 year-37.3%——
3-year CAGR-49.5%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2026
2.2M USD
Year-over-year change
-37.3%
4-year CAGR
-46.0%

Total Debt vs competitors

How IBIO compares with its peers on the latest reported figures

  • IBIO's Jun 2026 total debt of $2.2M is the 2nd highest of the 4 companies compared; the peer median is $154K.
  • Its year-over-year change of -37.3% is the lowest of 3, against a peer median of +16.1%.
  • Total debt amounts to 2.2% of total assets for IBIO, versus a peer median of 0.3%.
IBIO Competitors Peer median
Total Debt for IBIO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BOLDBoundless Bio, Inc.Mar 2026$48.29M -0.6%+111.5%34.3%
IBIOiBio, Inc.Jun 2026$2.2M -37.3%-49.5%2.2%
RLYBRallybio CorporationMar 2026$154K +32.8%-31.8%0.3%
ANTXAN2 Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding IBIO) $154K+16.1%+39.8%0.3%

Competitors are the stored peer set for IBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Cash & Equivalents22.68M7.33M14.21M8.58M56.4M
Short-term Investments10.85M00031.64M
Net Receivables6.1M204K713K105K1.1M
Inventory3.9M0000
Other Current Assets018.73M749K1.03M3.08M
Total Current Assets45.07M26.26M15.67M9.72M92.22M
Property, Plant & Equipment (Net)41.76M7.55M6.37M5.28M4.75M
Goodwill00000
Intangible Assets4.85M5.39M5.37M6.85M1.83M
Long-term Investments7.63M1.96M1.3M1.31M228K
Tax Assets(7.63M)0000
Other Non-current Assets7.73M50K26K26K83K
Total Non-current Assets54.34M14.95M13.06M13.46M6.89M
Total Assets99.41M41.21M28.73M23.19M99.11M
Account Payables4.26M1.85M358K2.19M4.42M
Short-term Debt22.16M13.6M218K766K0
Tax Payables284K268K000
Deferred Revenue100K0200K1.2M0
Other Current Liabilities754K2.52M761K876K6.78M
Total Current Liabilities30.44M21.58M3.84M6.11M11.75M
Long-term Debt00766K00
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.97M768K63K00
Total Non-current Liabilities5.49M4.24M3.57M2.2M1.65M
Total Liabilities35.92M25.83M7.41M8.31M13.4M
Common Stock9K20K9K19K56K
Retained Earnings(223.93M)(288.94M)(313.85M)(332.22M)(365.27M)
Accumulated OCI(213K)000(45K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity63.49M15.38M21.32M14.88M85.71M
Total Debt25.77M17.07M4.46M3.51M2.2M
Net Debt3.09M9.75M(9.75M)(5.07M)(54.2M)

iBio, Inc.

NASDAQ:IBIO

Intrinsic Alpha fair value

Locked

Current Price

$0.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.